Page 51 - Read Online
P. 51

Page 22 of 22                                       Guerriero et al. Hepatoma Res 2019;5:6  I  http://dx.doi.org/10.20517/2394-5079.2018.108


                   hepatitis B virus infection. Int J Clin Exp Med 2015;8:18462-8.
               144. Zheng F, Liao YJ, Cai MY, Liu TH, Chen SP, et al. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in
                   vivo by repressing multiple targets. PLoS Genet 2015;11:e1004873.
               145. Xu Y, Bu X, Dai C, Shang C. High serum microRNA-122 level is independently associated with higher overall survival rate in
                   hepatocellular carcinoma patients. Tumour Biol 2015;36:4773-6.
               146. Zhuang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int
                   2015;2015:731781.
               147. Cho HJ, Kim JK, Nam JS, Wang HJ, Lee JH, et al. High circulating microRNA-122 expression is a poor prognostic marker in patients
                   with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clin Biochem 2015;48:1073-8.
               148. Kim SS, Cho HJ, Nam JS, Kim HJ, Kang DR, et al. Plasma MicroRNA-21, 26a, and 29a-3p as predictive markers for treatment
                   response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Korean Med Sci 2018;33:e6.
               149. Cho HJ, Kim SS, Nam JS, Kim JK, Lee JH, et al. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients
                   with hepatocellular carcinoma who underwent curative treatment. Clin Res Hepatol Gastroenterol 2017;41:181-9.
               150. Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J, et al. MicroRNA-34a expression levels in serum and intratumoral tissue can predict
                   bone metastasis in patients with hepatocellular carcinoma. Oncotarget 2016;7:87246-56.
               151. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, et al. Identification of a bona fide microRNA biomarker in serum exosomes
                   that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 2015;112:532-8.
               152. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is
                   increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids 2015;4:e233.
               153. El-Tawdi AH, Matboli M, Shehata HH, Tash F, El-Khazragy N, et al. Evaluation of circulatory RNA-based biomarker panel in
                   hepatocellular carcinoma. Mol Diagn Ther 2016;20:265-77.
               154. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int
                   2013;2013:136106.
               155. El-Tawdi AH, Matboli M, El-Nakeep S, Azazy AE, Abdel-Rahman O. Association of long noncoding RNA and c-JUN expression in
                   hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:869-77.
               156. Tang J, Zhuo H, Zhang X, Jiang R, Ji J, et al. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and
                   metastasis in hepatocellular carcinoma. Cell Death Dis 2014;5:e1549.
               157. Wang X, Zhang W, Tang J, Huang R, Li J, et al. LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an
                   epidermal growth factor receptor-dependent pathway. Cell Death Dis 2016;7:e2130.
               158. Tang J, Jiang R, Deng L, Zhang X, Wang K, et al. Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis
                   and metastasis in hepatocellular carcinoma. Oncotarget 2015;6:4505-15.
               159. Konishi H, Ichikawa D, Yamamoto Y, Arita T, Shoda K, et al. Plasma level of metastasis-associated lung adenocarcinoma transcript 1
                   is associated with liver damage and predicts development of hepatocellular carcinoma. Cancer Sci 2016;107:149-54.
               160. Jing W, Gao S, Zhu M, Luo P, Jing X, et al. Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncol Rep
                   2016;36:1085-92.
               161. Wang K, Guo WX, Li N, Gao CF, Shi J, et al. Serum LncRNAs profiles serve as novel potential biomarkers for the diagnosis of HBV-
                   positive hepatocellular carcinoma. PLoS One 2015;10:e0144934.
   46   47   48   49   50   51   52   53   54   55   56